S-Alpha Therapeutics
Software-based digital therapeutics for non-psychiatric medical needs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $8.4m Valuation: $43.5m | Series B | |
| Total Funding | 000k | ||
| USD | 2023 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Dealroom estimates
Related Content
S-Alpha Therapeutics, Inc. is a South Korean digital therapeutics (DTx) company founded in July 2019 by CEO Seung Eun Choi. Choi, a surgeon who was a pediatric surgery fellow at Seoul National University Hospital and a research professor at Pohang University of Science and Technology, established the firm to address diseases with high unmet medical needs through the convergence of information technology and biology.
The company develops evidence-based, software-as-a-medical-device (SaMD) products. Its business model centers on creating a pipeline of digital treatments across various therapeutic areas, including ophthalmology, neuropsychiatry, cancer, and immunology, and then licensing this technology to partners. S-Alpha Therapeutics' revenue is generated through these licensing agreements, such as the deal with Rohto Pharmaceutical for its pediatric myopia treatment.
The company's lead product is SAT-001, an investigational software treatment for pediatric myopia. This application uses a smartphone's camera to track eye movements, which control character movements within a game-like interface, an approach designed to enhance treatment efficacy and engagement for children. The product pipeline also includes SAT-008, which aims to boost the user's immune system. The company collaborates with academic and industry partners to advance its research and development programs.
S-Alpha Therapeutics has secured significant funding to support its clinical trials and R&D. Following an initial strategic investment from LegoChem Biosciences in February 2020, the company raised $2.7 million in a seed round in November 2020. This was followed by a Series A round of $8.7 million in July 2021 and subsequent Series B funding, bringing total investment to approximately $16.6 million by April 2024. The company is preparing for an initial public offering (IPO) targeted for late 2025.
Keywords: digital therapeutics, SaMD, ophthalmology, pediatric myopia, software as a medical device, immunology, neuropsychiatry, clinical trials, medical software, eye disease treatment, healthcare technology, DTx, therapeutic software, immune-boosting, digital health, startup